临床试验/NCT00103324

NCT00103324已完成2 期

Phase II Study of GW572016 (NSC-727989) as First Line Therapy in Patients With Advanced or Metastatic Gastric Cancer

National Cancer Institute (NCI)1 个研究点分布在 1 个国家目标入组 40 人开始时间: 2004年12月最近更新: 2013年1月17日

适应症

干预措施

试验速览

阶段: 2 期
状态: 已完成
发起方: National Cancer Institute (NCI)
入组人数: 40
试验地点: 1
主要终点: Confirmed response probability (complete and partial)

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This phase II trial is studying how well lapatinib works in treating patients with locally advanced or metastatic stomach cancer. Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth

详细描述

PRIMARY OBJECTIVES:

I. To assess the confirmed response (complete and partial) probability in patients with advanced/metastatic gastric cancer treated with GW572016.

II. To assess the time to treatment failure and overall survival in this group of patients.

III. To assess the qualitative and quantitative toxicities associated with this regimen.

IV. To assess, in a preliminary manner, the relationship of protein expression and gene expression of EGFR, HER2 and markers of angiogenesis with clinical outcomes in patients treated with GW572016.

研究设计

研究类型: Interventional
分配方式: Na
干预模型: Single Group
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Patients must have cytologically or pathologically verified diagnosis of gastric cancer; patients must have locally advanced or distant metastatic disease (either recurrent or at primary diagnosis) that is not surgically curable
•The pathologic confirmation of gastric cancer may be made from the metastatic site; biopsy of the primary tumor is not necessary; patients with pathologic confirmation of cancer from a metastatic site, along with clinical documentation of gastric involvement and no evidence of another primary are also eligible
•Eligible pathologic type: patients may have any histological subtype including adenocarcinoma NOS, papillary carcinoma, adenocarcinoma, intestinal type, clear cell adenocarcinoma, mucinous carcinoma, signet ring cell carcinoma, undifferentiated carcinoma, carcinoma NOS; patients must not have carcinoid tumors or sarcomas
•Patients must have measurable disease; x-rays, scans, or physical examinations for measurable disease must have been completed within 28 days prior to registration; x-rays, scans or physical examinations for non-measurable disease must have been completed within 42 days prior to registration,; all disease must be assessed
•Patients must be willing to have specimens submitted; the paraffin embedded specimens must be available for submission
•Patients may have had prior surgery for their gastric cancer; patients must be at least 2 weeks beyond surgery, and recovered from all effects of surgery
•Patients may have received prior chemotherapy, hormonal therapy, immunotherapy, radiation or chemoradiotherapy as neoadjuvant or adjuvant treatment but this must have been completed at least 6 months prior to documented recurrence or metastatic disease; patients must not have received previous treatment for metastatic disease
•If patient received radiation therapy, the site of measurable disease must be outside of the radiation field
•Patients must not have had prior therapy with EGFR targeting therapies
•Patients must have a Zubrod performance status of 0-1
•Leukocytes >= 3,000/mcl
•Platelets >= 100,000/mcl
•AGC >= 1,500/mcl
•Serum transaminase (SGOT or SGPT) =< 2.5 x IULN; patients with liver metastases must have SGOT/SGPT =< 5 x IULN
•Bilirubin =< IULN
•Serum creatinine =< IULN OR measured creatinine clearance > 60 mL/min OR estimated creatinine clearance> 60 mL/min
•Patients must have cardiac ejection fraction within the institutional range of normal as measured by echocardiogram or MUGA scan; note that baseline and on treatment scans should be performed using the same modality and preferably at the same institution
•Patients must either be able to swallow and/or receive enteral medications via gastrostomy feeding tube; patients with intractable nausea or vomiting are not eligible; patients with GI tract disease resulting in an inability to take oral medication, malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures affecting absorption, or uncontrolled inflammatory GI disease (e.g., Crohn's, ulcerative colitis) are not eligible
•Patients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to GW572016
•There must be no plans for the patient to receive concurrent chemotherapy, hormonal therapy, radiotherapy, immunotherapy or any other type of therapy for treatment of their cancer while on this protocol
•HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with GW572016
•Pregnant or nursing women are not eligible because of the risk of fetal harm; nursing women may participate only if nursing is discontinued, due to the possibility of harm to nursing infants from this treatment regimen; women/men of reproductive potential must have agreed to use an effective contraceptive method
•No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in remission or any other cancer from which the patient has been disease-free for 5 years
•If day 28 or 42 falls on a weekend or holiday, the limit may be extended to the next working day
•In calculating days of tests and measurements, the day a test or measurement is done is considered day 0; therefore, if a test is done on a Monday, the Monday four weeks later would be considered day 28; this allows for efficient patient scheduling without exceeding the guidelines
•All patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
•At the time of patient registration, the treating institution's name and ID number must be provided to the Statistical Center in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered into the data base

排除标准

未提供

研究组 & 干预措施

Treatment

Experimental

Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

干预措施: lapatinib ditosylate (Drug)

Treatment

Experimental

Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

干预措施: laboratory biomarker analysis (Other)

结局指标

主要结局

Confirmed response probability (complete and partial)

时间窗: Up to 2 years

次要结局

Time to treatment failure(From the date of registration to the date of first observation of progressive disease, death due to any cause, symptomatic deterioration, or early discontinuation of treatment, assessed up to 2 years)
Overall survival(From date of registration to date of death due to any cause, assessed up to 2 years)

研究者

发起方

National Cancer Institute (NCI)

申办方类型

Nih

责任方

Sponsor

研究点 (1)

Loading locations...

相似试验

已完成

2 期

Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By SurgeryAdult Primary Hepatocellular CarcinomaAdvanced Adult Primary Liver CancerLocalized Unresectable Adult Primary Liver CancerRecurrent Adult Primary Liver CancerRecurrent Extrahepatic Bile Duct CancerRecurrent Gallbladder CancerUnresectable Extrahepatic Bile Duct CancerUnresectable Gallbladder Cancer

NCT00101036National Cancer Institute (NCI)57

已完成

2 期

Lapatinib in Treating Patients With Recurrent or Persistent Endometrial CancerRecurrent Endometrial Carcinoma

NCT00096447National Cancer Institute (NCI)31

已完成

2 期

GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast CancerNeoplasms, Breast

NCT00320411GlaxoSmithKline62

已完成

2 期

Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate CancerRecurrent Prostate CancerStage I Prostate CancerStage IIA Prostate CancerStage IIB Prostate CancerStage III Prostate Cancer

NCT00103194National Cancer Institute (NCI)49

已完成

2 期

NCT00114283National Cancer Institute (NCI)30